Article info
PDFLetter
Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy
- Correspondence to Dr Océane Landon-Cardinal, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada; oceane.landon-cardinal{at}umontreal.ca
Citation
Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy
Publication history
- Received October 26, 2022
- Accepted December 24, 2022
- First published January 6, 2023.
Online issue publication
March 10, 2023
Article Versions
- Previous version (6 January 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.